Earnings Feed
Start Free
|8-KFeb 13, 5:29 PM ET

Sensei Biotherapeutics, Inc. 8-K

Research Summary

AI-generated summary

Updated

Sensei Biotherapeutics Appoints Two New Directors to Board

What Happened

  • Sensei Biotherapeutics, Inc. (SNSE) filed an 8-K reporting that on February 13, 2026 the board increased its size from three to five members and appointed Christopher W. Gerry and Phillip B. Donenberg as directors, effective immediately. Each will serve until a successor is elected or until earlier death, resignation or removal.
  • Christopher W. Gerry (age 46) is the Company’s President, Principal Executive Officer and General Counsel. Phillip B. Donenberg (age 65) is an experienced biotech finance executive and audit committee chair with prior CFO and board roles at multiple life sciences companies.

Key Details

  • Board change date: February 13, 2026; board size increased from 3 to 5 directors.
  • New directors: Christopher W. Gerry (46) and Phillip B. Donenberg (65).
  • Mr. Gerry’s background: current President/Principal Executive Officer and General Counsel of Sensei; previously General Counsel at Sensei since July 2022; prior roles at AVROBIO and Cooley LLP; B.A. Dickinson College; J.D. Boston University School of Law.
  • Mr. Donenberg’s background: board member/audit chair at Taysha Gene Therapies since Aug 2020 and Tectonic Therapeutic since June 2018; former SVP/CFO roles at Jaguar Gene Therapy, AveXis and Assertio; B.S. in accountancy (Univ. of Illinois) and CPA; will be paid under Sensei’s 2025 non-employee director compensation program.
  • Corporate formalities: no arrangements or understandings reported regarding their appointments; neither is party to transactions requiring Item 404(a) disclosure.
  • Indemnification: both will enter Sensei’s standard form of indemnification agreement (as filed as Exhibit 10.3 to the Company’s 2025 Form 10-K).

Why It Matters

  • This filing documents a governance change that immediately alters board composition and adds two directors with complementary backgrounds: an insider executive (Gerry) and a seasoned finance/audit director (Donenberg).
  • For investors, the change affects who oversees strategy, compliance and financial reporting. The filing discloses no related-party transactions and confirms standard indemnification and director compensation arrangements.